Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers a comprehensive portfolio of workflow solutions for biomarker discovery and drug development.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation develops unique assays for use in multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically-relevant markers combined with same slide-H&E analysis in precious tissue samples.
Fluidigm is a leader in high-parameter imaging for the clinical translational research and clinical testing markets. It’s Imaging Mass Cytometry™ (IMC™) technology is designed for highly multiplexed targeted interrogation of tissue sections for 40 or more protein markers in one scan, with distinct non-overlapping signals from element-labeled antibodies detected simultaneously for each sub-micrometer pixel.
The collaboration provides reseachers with end-to-end service capability for clinical and translational work. For example, InSituPlex technology is well suited to identify regions of interest that may require downstream, deep profiling with IMC™. Customer access to both technologies can improve the efficiency of drug discovery programs and, in translational research, enable patient stratification to triage cases that require further investigation.
“Imaging Mass Cytometry has become integral to the clinical translational research and clinical testing markets,” said Chris Linthwaite, Fluidigm President and CEO. “Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.”
“Ultivue is at the forefront of innovation to provide unique biological insights for our customers,” said Mark Rees, Vice-President of Business Development at Ultivue. “Our InSituPlex® technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities of Imaging Mass Cytometry. We believe this joint offering with Fluidigm will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.”
About Fluidigm
Fluidigm Corporation (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all.
Fluidigm, the Fluidigm logo, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. For Research Use Only. Not for use in diagnostic procedures. For more information, visit fluidigm.com.
About Ultivue
Ultivue, Inc. provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. For more information, visit ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005443/en/
Contact information
Ultivue
Mark Rees, PhD
Vice President Corporate Development
(+1) 516-512-4977
mark.rees@ultivue.com
Fluidigm
Mark Spearman
Senior Director, Corporate Communications
(+1) 650-243-6621
mark.spearman@fluidigm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P ® Services6.11.2025 18:11:00 EET | Press release
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Research Labs® (“Lab to Pharmacy”), further expanding its service portfolio, and bridging the translational research gap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106703527/en/ NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline Currently, the attrition rate of biological molecules moving past phase 1 clinical trials is very high and the way to overcome this challenge is through translational research. NJ Bio specializes in preclinical and early-phase clinical research and development, with a primary focus on ADCs, bioconjugation, custom synthesis, oligonucleotides, and mRNAs. Howe
DevvStream Reports Fiscal Year 2025 Results and Advances Digital-Asset and Tokenization Strategy6.11.2025 18:01:00 EET | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management and environmental-asset monetization firm, today announced financial results for its fiscal year ended July 31, 2025, and provided an update on strategic initiatives designed to enhance liquidity, expand technology capabilities, and position the Company for scalable, acquisition-driven growth. Fiscal 2025 Highlights Completed Nasdaq listing and de-SPAC transaction, establishing DevvStream as one of the few publicly traded pure plays in carbon and renewable-energy asset monetization. Closed initial $10 million tranche under the Helena $300 million convertible-note facility, providing liquidity to launch the Company’s digital-asset treasury. Reported initial revenue as the Company begins monetizing its environmental-asset pipeline. Successfully completed strategic investments and partnerships that expand DevvStream’s reach across carbon, renewable-energy, and environmental-credit markets. Strengt
BST Global Launches 2026 AI + Data Impact Survey for the AEC Industry6.11.2025 17:41:00 EET | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105615222/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. Conducted in partnership with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committee, the survey focuses s
Scientist.com Wins Supplier Management Excellence Award at B2B Ecommerce Awards6.11.2025 16:43:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform for the life sciences, has been named the winner of the Supplier Management Excellence award at the prestigious B2B Ecommerce Awards. The honor recognizes organizations that set new standards in supplier network innovation, integration, and performance to deliver superior customer value. “Winning this award is a tremendous honor and a testament to our team’s relentless focus on simplifying and accelerating R&D,” said Andrew Nashed, VP, Supplier Relations at Scientist.com. “Our platform automates and optimizes the complex process of supplier management, enabling scientists to focus on innovation while we handle compliance, integration, and operational efficiency.” Scientist.com was recognized for its industry-leading approach to building and managing the world’s largest network of scientific service providers. Its technology-driven platform connects pharmaceutical, biotech, and academic researchers with over 6,000 pre-qual
CoMotion GLOBAL 2025 Unveils ‘Mayors in Motion’ Initiative: 100+ City Leaders to Accelerate Urban Innovation6.11.2025 16:00:00 EET | Press release
CoMotion GLOBAL, the world’s most influential gathering of urban mobility leaders, today announced the launch of Mayors in Motion, a landmark initiative uniting more than 100 global mayors and city leaders to accelerate urban innovation and sustainable development. The program will debut at the upcoming CoMotion GLOBAL conference in Riyadh, December 7–9, underscoring the summit’s growing role as a catalyst for collaboration among the world’s most forward-thinking cities. Designed to drive progress toward more connected, sustainable, and inclusive cities, Mayors in Motion will serve as a powerful global network for city leaders to exchange insights, coordinate strategies, and champion practical solutions. Through this coalition, participating mayors will collaborate to address critical shared challenges – from decarbonization and digital transformation to equitable access and urban resilience. The inaugural program features an exceptional lineup of current and former mayors alongside se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom